

Answers That Matter.

Fast Facts

A heritage more than 131 years strong: company founded on May 10, 1876

More than 41,000 employees worldwide

Approximately 7,980 employees engaged in research and development

Clinical research conducted in more than 50 countries

Research and development facilities located in 8 countries

Manufacturing plants located in 13 countries and territories

Introduced

Byetta[®], first-in-class incretin mimetic used by patients with type 2 diabetes to control blood sugar levels

Cymbalta[®], for major depressive disorder and diabetic peripheral neuropathic pain

Alimta[®], the first and only chemotherapy regimen approved by the FDA to treat patients with malignant pleural mesothelioma who are not candidates for surgery

Symbyax[®], for bipolar depression

Yentreve[®], for stress urinary incontinence (not approved in the U.S.)

Cialis[®], a distinctive new treatment for erectile dysfunction from the Lilly ICOS joint venture

Strattera[®], the first FDA-approved nonstimulant, noncontrolled medication for the treatment of attention-deficit hyperactivity disorder in children, adolescents, and adults

Forteo[®], first-in-class medicine for osteoporosis patients that stimulates new bone formation

Xigris[®], the first treatment approved for adult severe-sepsis patients at a high risk of death

Evista[®], the first in a new class of drugs for the prevention and treatment of postmenopausal osteoporosis

Zyprexa[®], Lilly's breakthrough product for schizophrenia and acute mania associated with bipolar disorder

Humalog[®], a fast-acting insulin product

Gemzar[®], for pancreatic and non-small-cell lung cancer, one of the world's best-selling oncology agents

Humatrope[®], therapy for growth hormone deficiency

Prozac[®], which revolutionized the treatment of depression

Humulin[®], human insulin, the first human-health-care product created by biotechnology

Ceclor[®], which became the world's top-selling oral antibiotic

Iletin[®], the first commercially available insulin product, in 1923

Established

A pioneering initiative to treat multi-drug resistant tuberculosis (MDR-TB), one of the deadliest public health threats in the world. In collaboration with the World Health Organization, the U.S. Department of Health and Human Services Centers for Disease Control and Prevention, Brigham and Women's Hospitals of Harvard Medical School, and Purdue University, Lilly is providing low-cost antibiotics, training for international medical personnel, and technology to enable the manufacture of products for treatment in China, India, and South Africa.

Named

One of the 100 Best Companies to Work for in America (six consecutive years) by *Fortune* magazine

One of the Best Companies for Working Mothers (in the top 10 for the sixth time in 10 years) by *Working Mother* magazine

One of the Global Most Admired Companies by *Fortune* magazine

Who We Are

Lilly is a leading innovation-driven pharmaceutical corporation. We are developing a growing portfolio of best-in-class, first-in-class pharmaceutical products by applying the latest research from our own worldwide laboratories, by collaborating with eminent scientific organizations, by making use of the most advanced technological tools, and by providing exceptional service to our customers.

Through internal programs and external initiatives, we're seeking answers for some of the world's most urgent medical needs. As our products save and improve lives, they also save overall health care costs: they are often less expensive than other forms of health care, such as surgery and hospitalization.

We employ more than 41,000 people worldwide and market our medicines in 143 countries. Lilly has major research and development facilities in 8 countries and conducts clinical trials in more than 50 countries.

What We Do

Everything at Lilly begins with the unmet medical needs of people. We provide answers for these often complex, difficult problems in two ways: through the discovery and development of breakthrough medicines and through the health information we offer.

We are strengthening our ability to identify high-potential drug candidates by improving our research and development processes, investing in new technologies, and adding new scientific talent. At the same time, we have entered into dozens of alliances worldwide to gain access to new research capabilities and additional promising compounds.

To ensure that our customers get the maximum benefits from our products, we provide important information about our medicines and the diseases they treat. In this way, among others, we continue our company's tradition of providing exceptional customer service.

We are working to make sure patients have access to the medicines they need. We help low-income and uninsured patients in the U.S. through our Lilly Cares™ program and voluntarily provide discounts on products for state-sponsored patient-assistance programs. At the same time, we are actively involved in lobbying and advocacy efforts to help expand access to medical care and medicines.

As our company touches the lives of people worldwide, we recognize that we have a responsibility to be a good corporate citizen in the communities we affect and to help preserve the environment for the generations to come.

Our Values

As we implement our strategies and pursue our objectives, long-established core values guide us in all that we do:

Respect for people, which includes our concern for the interests of all the people worldwide who touch—or are touched—by our company: customers, employees, shareholders, partners, suppliers, and communities

Integrity that embraces the very highest standards of honesty, ethical behavior, and exemplary moral character

Excellence that is reflected in our continuous search for new ways to improve the performance of our business to become the best at what we do.

Lilly Mission

We provide customers “Answers That Matter” through innovative medicines, information, and exceptional customer service that enable people to live longer, healthier, and more active lives.

Our Brand: Answers That Matter

We endeavor to be a company with whom stakeholders—patients, employees, physicians, shareholders, and others—prefer to work and interact. And we know this is less about what we say and more about what we do. Therefore, through our *actions*, we want stakeholders to view Lilly as providing “Answers That Matter” by delivering breakthrough products and medical expertise, actively listening and responding, and being reliable and trustworthy in all that we do.

- Our commitment to *breakthrough products* means that we focus our considerable investment in research and development of new medicines not only on responding to market opportunities but also on meeting unmet patient needs.
- *Medical expertise* enables the research, discovery, and development of new medicines. We also want to share that expertise by increasing access to medicines through programs such as Lilly Cares™, which provides free medicine (through physicians) to qualifying low-income U.S. patients, and the Lilly Multi-Drug Resistant Tuberculosis Partnership, a global initiative to address the rising incidence of MDR-TB.
- *Active listening and responding* describes how we engage with our internal and external stakeholders. Listening builds understanding of our stakeholders’ wants and needs and provides insight into markets, emerging policy and regulatory issues, and community and customer concerns. Responding builds trust and assures stakeholders that their concerns have been taken seriously.
- Our pledge to be *reliable and trustworthy* demonstrates our intention to build trust in our company and our industry.

Lilly Research Laboratories

Our research division, Lilly Research Laboratories (LRL), is responsible for the discovery, development, and clinical evaluation of our pharmaceutical products and for providing ongoing scientific support for marketed products. At the core of LRL's mission is discovering and developing innovative therapies for many of the world's unmet medical needs.

LRL comprises approximately 7,980 people from a wide variety of scientific disciplines who work in laboratories in the United States and at other locations around the world. Research and development locations in the United States include sites in Indiana (Indianapolis and Greenfield) as well as in California.

Outside the U.S., our research and development facilities are located in Australia, Canada, China, England, Japan, Singapore, and Spain. Lilly conducts clinical research in more than 50 countries.

Therapeutic Areas: Targeting Unmet Medical Needs

Our mission includes finding answers for some of the world's most urgent medical needs. We focus our internal research efforts primarily on neuroscience, endocrine disorders, cancer, cardiovascular diseases, inflammation, and bioproduct discovery. We also continue to pursue innovative science and new opportunities beyond our targeted disease categories. We embrace a philosophy of "research innovation without walls," meaning that we pursue cutting-edge science and technology from external, as well as internal, sources.

Partnering for Success

At Lilly, we are committed to innovation and the success of our partnerships.

We were the first in our industry to establish an office of alliance management. Nearly a century ago, an alliance partner helped us produce the world's first commercial insulin product. Another partner worked with us to bring the world its first human biotech product—human insulin.

Today, partnerships continue to be a key component of our strategy for the future. Our more than 100 active alliance partnerships run the gamut from discovery to development to commercialization. Lilly has been recognized by several independent surveys and by academic experts as a leader in alliance management.

Innovative Initiatives

As a leading innovation-driven pharmaceutical corporation, Lilly uses all possible avenues to achieve excellence and keep abreast of new tools, technologies, and business models as they develop. At the same time, it is our goal to be recognized as the pharmaceutical industry's premier business partner. It follows naturally for us to seek innovation from all sources.

Examples include:

- **e.Lilly**—established in 2000 to explore the transformative impact of novel business models and Internet technology to radically speed up and improve the implementation of company goals. In August 2005, most of the e.Lilly organization moved into the company's New Ventures operations to better leverage e.Lilly's capabilities across the entire Lilly organization.
- **Lilly Ventures**—the venture capital arm of Lilly, which is now part of the New Ventures organization. Lilly Ventures (www.lillyventures.com) currently manages \$175 million targeting three investment areas. These investments support early- to expansion-stage companies developing innovative technologies and novel therapies to address some of the world's most urgent medical needs.
- **InnoCentive, Inc.**—uses the power of the Internet to create and enhance open innovation in scientific research and development. Through InnoCentive (www.innocentive.com), companies post scientific challenges to a worldwide audience of talented scientists who are willing to find answers to the problems. Those who present the most innovative solutions receive cash awards in varying amounts.

Global Manufacturing and Quality

Lilly manufactures its breakthrough medicines at 20 sites in 13 countries and territories around the world. The organization's mission is to ensure a reliable supply of high-quality medicine safely, while remaining in a state of compliance and continuously improving.

The MQ organization comprises about 12,000 Lilly employees who make active pharmaceutical ingredients and finished drug products, including tablets, capsules, vials, cartridges, and freeze-dried preparations—as well as such drug-delivery devices as injection pens. The organization also manages relationships with numerous contract manufacturing organizations and other partners, ensuring that those firms meet Lilly standards and support the Lilly brand in supplying medicines to patients globally.

Lilly manufacturing sites are located in the continental United States in Terre Haute, Lafayette, and Indianapolis, Indiana. In Puerto Rico, Lilly operates sites at Carolina and Guayama. Manufacturing sites outside the United States are located in the United Kingdom, Ireland, Spain, Germany, France, Italy, Japan, China, Brazil, Egypt, and Mexico.

Marketing and Sales

Lilly's approach to creating and realizing global demand for its innovative brands begins and ends with our customers—patients, providers, and payers. That's what we mean by demand realization. It's every activity by a Lilly employee that increases the value we bring to customers and that ultimately leads to a customer choosing a Lilly brand.

Marketing and sales colleagues work across regions with program teams, brand development teams, and affiliates to ensure the success of new brand launches and to meet customers' needs. Marketing planning begins early in a product's development and continues through the life cycle until the patent expires. Teams prioritize marketing and sales initiatives and effectively implement action plans to deliver better patient outcomes. Marketing campaigns leverage multiple channels, including direct-to-consumer, e-detailing, and peer-to-peer meetings—all to provide information in the most efficient way for our customers. With the right tools, the right information, and Lilly's innovative products, it's up to Lilly's sales representatives to complete the critical interaction with our customers. The ultimate goal of marketing and sales is clear—to help patients live longer, healthier lives.

Innovation from the Lilly Pipeline

Major Marketed Products

(Dates indicate the year of first global launch)

2005	Byetta [®]	for type 2 diabetes <i>(codeveloped with Amylin Pharmaceuticals, Inc., and copromoted with Amylin in the U.S.)</i>
2004	Cymbalta [®]	for major depressive disorder for diabetic peripheral neuropathic pain (2004) <i>(copromoted with Quintiles Transnational Corp. in the U.S., and with Boehringer Ingelheim elsewhere in the world, except Japan)</i>
	Alimta [®]	for malignant pleural mesothelioma for second-line treatment of non-small-cell lung cancer (2004)
	Symbyax [®]	for bipolar depression
	Yentreve [®]	for stress urinary incontinence (approved and launched outside the U.S.)
2003	Cialis [®]	for erectile dysfunction
	Strattera [®]	for attention-deficit hyperactivity disorder in children, adolescents, and adults
2002	Forteo [®]	for treatment of men and postmenopausal women with osteoporosis who are at high risk for a fracture
2001	Xigris [®]	for adult severe sepsis patients at high risk of death
1999	Actos [®]	for type 2 diabetes <i>(developed by Takeda Chemical Industries, Ltd., and copromoted with Takeda)</i>
1998	Evista [®]	for prevention of osteoporosis in postmenopausal women for treatment of osteoporosis in postmenopausal women (1999)
1996	Zyprexa [®]	for schizophrenia for acute bipolar mania (2000) Zyprexa [®] Zydis [®] tablet (2000) for schizophrenia maintenance (2001) as combination therapy with lithium or valproate for acute bipolar mania (2002) for bipolar maintenance (2003) Rapid-acting IntraMuscular formulation (2004) Zyprexa [®] granules (2004; launched in Japan only)
	Humalog [®]	for treatment of type 1 and type 2 diabetes Humalog [®] mixtures (1999) Humalog [®] Mix 50/50 (1999)
1995	Gemzar [®]	for non-small-cell lung cancer for pancreatic cancer (1996) for bladder cancer (1999; approved and launched outside the U.S.) for metastatic breast cancer (2003) for recurrent ovarian cancer (2004)
	ReoPro [®]	for prevention of cardiac ischemic complications in patients undergoing coronary intervention, such as angioplasty for unstable angina associated with stent procedure (1997) <i>(developed by Centocor and promoted by Lilly, except in Japan)</i>

(Continued on next page)

Trademarks Actos[®] (pioglitazone hydrochloride, Takeda); Alimta[®] (pemetrexed disodium, Lilly); Byetta[™] (exenatide injection, Amylin Pharmaceuticals, Inc.); Ceclor[®] (cefactor, Lilly); Cialis[®] (tadalafil, Lilly); Coban[®] (liraglutide sodium, Elanco); Cymbalta[®] (duloxetine hydrochloride, Lilly); Elector[®] (spinosad, Elanco); Evista[®] (raloxifene hydrochloride, Lilly); Forteo[®] (teriparatide of recombinant DNA origin, Lilly); Gemzar[®] (gemcitabine hydrochloride, Lilly); Humalog[®] (insulin lispro of recombinant DNA origin, Lilly); Humatrope[®] (somatropin of recombinant DNA origin, Lilly); Humulin[®] (human insulin of recombinant DNA origin, Lilly); Iletin[®] (insulin, Lilly); Micotil[®] (lithium carbonate, Elanco); Paylean[®] (ractopamine, Elanco); Prozac[®] (fluoxetine hydrochloride, Lilly); Putmotil[®] (lithium carbonate, Elanco); Reconcile[®] (fluoxetine hydrochloride, Lilly); ReoPro[®] (abciximab, Centocor), Lilly; Rumensin[®] (liraglutide sodium, Elanco); Strattera[®] (atomoxetine hydrochloride, Lilly); Symbyax[®] (lithium carbonate/fluoxetine hydrochloride, Lilly); Tylan[®] (tylosin, Elanco); Xigris[®] (drotrecogin alfa (activated), Lilly); Yentreve[®] (duloxetine hydrochloride, Lilly); Zyprexa[®] (olanzapine, Lilly).

Actos[®] is a trademark of Takeda Chemical Industries, Ltd. Byetta[®] is a trademark of Amylin Pharmaceuticals. Cialis[®] is a trademark of Lilly ICOS LLC. Zydis[®] is a trademark of Cardinal Health.

Innovation from the Lilly Pipeline (Continued from previous page)

Major Marketed Products		<i>(Dates indicate the year of first global launch)</i>
1987	Humatrope®	for growth failure caused by pediatric growth hormone deficiency for replacement therapy for adult growth hormone deficiency (1995) for short stature caused by Turner syndrome (1997) for idiopathic short stature (2003)
1983	Humulin®	for type 1 and type 2 diabetes

Select Drug Candidates in Late-Stage Investigation

Prasugrel	for acute coronary syndromes <i>(codeveloping with Daiichi Sankyo Company, Ltd.)</i>
Inhaled insulin	for type 1 and type 2 diabetes <i>(codeveloping with Alkermes, Inc.)</i>
Arzoxifene	for prevention and treatment of osteoporosis and for reducing the risk of breast cancer, all in postmenopausal women
Enzastaurin	for non-Hodgkin's lymphoma (Phase III); for metastatic breast cancer, colorectal cancer, non-small-cell lung cancer, and ovarian cancer (Phase II)
Olanzapine pamoate	for intramuscular delivery for schizophrenia

Select Drug Candidates in Mid-Stage Investigation

Pruvanserin (5-HT2A antagonist)	for insomnia
PPAR alpha agonist (LY518674)	for reducing the progression of atherosclerosis
Survivin ASO	for solid tumors
A-beta lowering (Gamma secretase inhibitor)	for Alzheimer's disease
A-beta antibody	for Alzheimer's disease
ASAP	for solid tumors
mGluR3 antagonist	for migraine
NERI IV	for depression (Phase II); for ADHD (Phase I)
mGlu2/3 prodrug	for schizophrenia
IL-1 beta antibody	for rheumatoid arthritis
Gemcitabine prodrug	for solid tumors
GLP-1 analog	for type 2 diabetes
Glucokinase activator	for type 2 diabetes <i>(recently in-licensed from OSI Pharmaceuticals, Inc.)</i>

Information is current as of March 31, 2007. The search for new drugs is risky and uncertain, and there are no guarantees. Remaining scientific and regulatory hurdles may cause pipeline compounds to be delayed or even to fail to reach the market.

Elanco Animal Health

A division of Eli Lilly and Company, Elanco is a global research-based company that develops and markets products to improve the health and production of animals. Elanco products enhance animal wellness, welfare, and performance to help the food industry produce an abundant supply of safe, nutritious, and affordable food.

Elanco has developed several leading products including:

- **Tylan**[®], the first antibiotic developed exclusively for agricultural use in pigs, cattle, and poultry
- **Coban**[®], widely used in chickens to prevent coccidiosis, a common poultry disease
- **Rumensin**[®], helps cattle get more energy from rations and prevents/controls coccidiosis
- **Paylean**[®], increases the amount of quality meat while improving gain and feed efficiency in swine
- **Elector**[®], controls external parasites including horn flies and lice.

With key operations in North America, Europe, the Middle East, Africa, the Asia-Pacific area, and Latin America, Elanco employs approximately 2,000 people and markets its products in more than 100 countries.

Companion Animal Health Group

In January 2007, Elanco launched a companion animal health group that will market medicines for dogs and cats under the Lilly brand. The group's first product, Reconcile[™], is a chewable, flavored tablet for dogs given once a day for the treatment of separation anxiety in conjunction with behavior modification training.

Lilly Takes Big Steps to Meet Urgent Medical Needs

We know the best medicines can't help people unless people have access to them. In the United States and globally, we are breaking ground in our innovative approaches to partnerships, working with governments and non-government organizations to ensure that patients have access to the medicines they need.

In September 2006, Lilly received a favorable opinion from the U.S. government for an innovative "Outside Part D" Medicare Part D patient assistance program, LillyMedicareAnswers, which will provide Zyprexa, Forteo, and Humatrope to low-income seniors who experience gaps in prescription coverage.

The program was designed to provide assistance to low-income Medicare Part D-enrolled patients most vulnerable to continuity-of-care issues. LillyMedicareAnswers meshes with Medicare Part D to provide more sophisticated medicines to the low-income patients who need them.

Patients enrolled in LillyMedicareAnswers pay only a \$25 administrative fee for each 30-day supply of medicines shipped directly to their home. Enrollment began in December 2006, with full operations beginning in January 2007.

Lilly undertook several measures in 2006 to help Medicare patients while awaiting the government opinion on this new program, including extending its long-standing LillyAnswers® program until December 31, 2006. Additionally, Lilly extended access to Forteo and Zyprexa for patients who were previously enrolled in the program and signed up for a Medicare Part D Plan.

This was one way Lilly offered seniors and low-income patients affordable access to drugs. Additionally, in 2006, the company donated products through six patient assistance programs that aided nearly 400,000 people in the United States. Lilly Cares, which offers free medicines to patients who cannot pay for them, helped more than 158,000 participants, while LillyAnswers provided low-cost prescriptions to nearly 235,000 Medicare-enrolled individuals. Other assistance programs helped patients gain reimbursement or access to drugs that battle cancer, severe sepsis, osteoporosis, and diabetes.

Setting the Pace for MDR-TB Partnerships

To halt the spread of one of the most pervasive and deadly diseases facing the world today, Lilly continued to partner with the World Health Organization and other groups to share expertise, transfer technology, improve treatment—and save lives. Tuberculosis—specifically, multi-drug resistant (MDR) TB—is a growing global concern, with more than 2 million people dying of the disease each year. Even the United States saw a 13 percent increase in the number of reported cases from 2004 to 2005. Recently, a new deadly strain was identified in South Africa, called XDR-TB (extensively drug-resistant TB). In response to the South African government's request, Lilly sent 3,000 vials of the antibiotic capreomycin to help to contain the outbreak, and provided funds to train doctors and nurses on proper treatment protocols.

During a November 2006 MDR-TB Summit in Paris, Lilly's government and non-government-organization partners formally recognized our company's approach to getting various groups to work together against this deadly scourge of TB. Our plans are moving forward to share technology so others can, independently, make our TB medicines: Our South African partner, Aspen, is producing one of our two antibiotics used to treat TB, while Hisun, our partner in China, expects to produce capreomycin by the end of 2007.

Thanks to a Lilly grant, the World Health Organization has provided extensive technical assistance to many countries. In China alone, several hundred doctors and nurses have been trained and more than 20,000 MDR-TB patients have been enrolled. Further, teams from The Harvard Kennedy School, INSEAD in Paris, and Indiana University have spent time with Lilly and its partners to understand the success of our model partnerships.

(Continued on next page)

Lilly Takes Big Steps to Meet Urgent Medical Needs (Continued from previous page)

A History of Giving

These and other initiatives in 2006 follow the Lilly commitment to providing “Answers That Matter,” as we maintain an honored tradition of giving back to the communities where we live and work. The company’s global philanthropy in 2006 totaled about \$420 million. Contributions included nearly \$350 million (net wholesale value) worth of product donations for patient assistance programs and international humanitarian causes. Lilly and its philanthropic foundation also gave more than \$57 million in cash donations for several urgent or special causes, and more than \$13 million in other in-kind contributions.

In the U.S., Lilly employees also donated generously to United Way charities; their contributions, combined with matches from the foundation, totaled \$9.7 million.

“Whether patients are seeking medicine, medical expertise, or both, we do our best to ensure that people in need are not forgotten,” said Chairman Sidney Taurel. “Our founders established these values more than 130 years ago, and we live by them today.”

Earning Society’s Trust

The depth and breadth of Lilly’s corporate good works might surprise you. For a full report on these initiatives, as well as challenges that lie ahead, visit www.lilly.com/about/citizenship.

There, you can learn more about how Lilly is earning society’s trust by establishing the first online clinical trial registry (www.lillytrials.com), working to improve the industry’s good promotional practices and code of ethics; respecting the environment, partnering with world health leaders to combat MDR-TB with the goal of treating 20,000 patients annually by 2010 (www.lillymdr-tb.com), and implementing a broad range of other programs that improve the lives of patients every day.

If You Would Like to Know More

Find specific information about the following topics on our website, www.lilly.com

Access to medicines

www.lilly.com/products/access/index.html

Awards and recognition

www.lilly.com/about/awards/

Corporate citizenship

www.lilly.com/about/citizenship

Corporate policies

www.lilly.com/about/policies/

Health, safety, and environment

www.lilly.com/about/policies/#envir

History

www.lilly.com/about/history.html

Investor relations

<http://investor.lilly.com>


Position on key issues

www.lilly.com/about/key_issues.html

Products

www.lilly.com/products/index.html

Eli Lilly and Company *Information 2007*



LILLY GLOBAL PRESENCE

	Sales Office	Manufacturing	Research				
	●	▲	■	Germany	●	▲	
				Greece	●		
				Honduras	●		
				Hong Kong	●		
Algeria	●			Hungary	●		
Argentina	●			Iceland	●		
Australia	●		■*	India	●		
Austria	●			Indonesia	●		
Belgium	●			Ireland	●	▲	
Bosnia-Herzegovina	●			Israel	●		
Brazil	●	▲		Italy	●	▲	
Bulgaria	●			Japan	●	▲	■
Canada	●		■	Kazakhstan	●		
Chile	●			Lebanon	●		
China	●	▲	■*	Lithuania	●		
Colombia	●			Malaysia	●		
Costa Rica	●			Mauritius	●		
Croatia	●			Mexico	●	▲	
Czech Republic	●			Morocco	●		
Denmark	●			Netherlands	●		
Dominican Republic	●			New Zealand	●		
Egypt	●	▲		Norway	●		
El Salvador	●			Pakistan	●		
Estonia	●			Panama	●		
Finland	●						
France	●	▲					
				Peru	●		
				Philippines	●		
				Poland	●		
				Portugal	●		
				Puerto Rico	●	▲	
				Romania	●		
				Russia Federation	●		
				Saudi Arabia	●		
				Serbia and Montenegro	●		
				Singapore	●		■
				Slovak Republic	●		
				Slovenia	●		
				South Africa	●		
				Spain	●	▲	■
				Sweden	●		
				Switzerland	●		
				Taiwan	●		
				Thailand	●		
				Tunisia	●		
				Turkey	●		
				Ukraine	●		
				United Arab Emirates	●		
				United Kingdom	●	▲	■
				United States	●	▲	■
				Venezuela	●		
				Vietnam	●		

*Joint ventures